9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019
The DOI matches its Crossref record; 77 of the 81 references it cites were found in a registry or an index.
Abstract
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations, please refer to the Standards of Care Introduction. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although SGLT2 inhibitor use was not incorporated into American Diabetes Association guidelines until 2019,48”
From Association of race/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US (2021) · cites this paper as [48]
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“Metformin is effective and safe, is inexpensive, and may reduce risk of cardiovascular events and death (40).”
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Maruthur, N. M., Tseng, E., Hutfless, S., Wilson, L. M., Suarez-Cuervo, C., Berger, Z., Chu, Y., Iyoha, E., Segal, J. B., & Bolen, S. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2650 · Cited by 682
Threshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652
Research works printed but not linked: 6
- Peters, 2013, American Diabetes Association/JDRF Type 1 Diabetes Sourcebook
- Chiang, 2014, Type 1 diabetes through the life span: a position statement of the American Diabetes Association
- Lexicon Pharmaceuticals . FDA to review ZynquistaTM (sotagliflozin) as potential treatment for type 1 diabetes [Internet], 2018. Available from http://www.lexpharma.com/media-center/news/673-fda-to-review-zynquista-sotagliflozin-as-potential-treatment-for-type-1-diabetes. Accessed 30 September 2018
- Institute for Clinical and Economic Review . Controversies in the management of patients with type 2 diabetes [Internet], December 2014. Available from https://icer-review.org/wp-content/uploads/2015/03/CEPAC-T2D-Final-Report-December-22.pdf. Accessed 9 November 2018
- Lipska, 2018, Association of initiation of basal insulin analogs vs neutral protamine Hagedorn insulin with hypoglycemia-related emergency department visits or hospital admissions and with glycemic control in patients with type 2 diabetes, 53
- Lipska, 2017, Human insulin for type 2 diabetes: an effective, less-expensive option, 23
Cited by
Items 701–773 of 773
An Age of Sodium-Glucose Cotransporter-2 Inhibitor Priority: Are We Ready?
Seo, J. A. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2019.0173
Leçons des grandes études cardiovasculaires et rénales portant sur les nouveaux antidiabétiques
Halimi, S. (2019) · Archives of Cardiovascular Diseases Supplements · doi:10.1016/s1878-6480(19)30960-7
Handelsman, Y., Muskiet, M. H. A., & Meneilly, G. S. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01185-0
Managing Older Adults with Type 2 Diabetes
Hershey, D. S. (2020) · Advances in Family Practice Nursing · doi:10.1016/j.yfpn.2020.01.001
Metformin Toxicity in Acute Kidney Injury. A Rare Cause of Severe Lactic Acidosis
Ajmal, M. S., Vinod, S., & Yan, J. (2019) · doi:10.37421/jnt.2019.9.332
Stefanović, T., Bosić, S., Vekić, J., Spasojević‐Kalimanovska, V., Todorović, V., Pijanović, M., Zeljković, A., Stefanović, A., & Jelić‐Ivanović, Z. (2019) · Arhiv za farmaciju · doi:10.5937/arhfarm1902051x
Cohen, C. M., Banon, T., Shalev, V., & Chodick, G. (2020) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.124
Yu, X., Zhang, L., Yu, R., Yang, J., & Zhang, S. (2020) · PLoS ONE · doi:10.1371/journal.pone.0230123
Neue Empfehlungen zur Therapie des Typ-2-Diabetes
Müller‐Wieland, D. (2020) · CardioVasc · doi:10.1007/s15027-020-2106-z
Vally, M. (2020) · South African General Practitioner · doi:10.36303/sagp.2020.1.1.0006
Part I: Continuous glucose monitoring systems
Moorman, J. M. (2020) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.1260
Gitto, S., & Andreoné, P. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.08.003
Žunić, T., & Ponjavić, M. (2020) · Arhiv za farmaciju · doi:10.5937/arhfarm2004198q · Cited by 1
Masuda, C., Randall, R., & Ortiz, M. (2020) · Pharmacy · doi:10.3390/pharmacy8030158
Mirzazada, V., Huseynova, R., Mustafayeva, S., Gasimova, F., Ahmadova, U., Ismayilova, N., Kerimova, V., Mehdiyeva, H., Suleymanova, R., Maharramova, Z., et al. (2020) · Journal of Diabetology · doi:10.4103/jod.jod_5_20 · Cited by 1
Nuñez-Musa, R. A., Sellés, A. J. N., Rossi, W. M., Marmolejos, R. G., Martínez-Sánchez, G., & Selman-Almonte, A. (2020) · Ciencia y Salud · doi:10.22206/cysa.2020.v4i3.pp71-93
Diabetes type 1 and type 2—Insulin delivery systems
Wong, E., Vadlapatla, R., & Morello, C. M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819838-4.00017-1
Hypoglycemic Therapy in Chronic Hepatic Disease Literature Review
Imbeth‐Acosta, P. L., Pájaro-Galvis, N., Leal-Martínez, V., Rico-Fontalvo, J. E., Daza-Arnedo, R., Castañeda-López, O., Cardona-Blanco, M., Mercado-Anillo, K., Lucas-Daza, J., Pérez-Calvo, C., et al. (2020) · Open Journal of Endocrine and Metabolic Diseases · doi:10.4236/ojemd.2020.1010013
Westman, K., Imberg, H., Albrektsson, H., Hirsch, I. B., Tuomilehto, J. O., Dahlqvist, S., & Lind, M. (2020) · Primary care diabetes · doi:10.1016/j.pcd.2020.11.005
A insustentável leveza do toque: reconhecimento do cuidado ao pé diabético
Fernandes, D. M. A. P., de Melo, V. F. C., de Assis, L. M. B., Pinheiro, M. D. L., de Morais, M. M. M., & Batista, M. C. D. A. R. (2021) · Saúde Coletiva (Barueri) · doi:10.36489/saudecoletiva.2021v11i61p4808-4817
Principles of pharmacological therapy of comorbid diseases in patients with orthopedic pathology
Prytula, N., Fedotova, I., & Korzh, I. (2021) · ORTHOPAEDICS TRAUMATOLOGY and PROSTHETICS · doi:10.15674/0030-59872020464-71
Evaluation of the metformin initiation rate in veterans with newly identified type 2 diabetes
Zenti, K. J., Meyer, M. M., Waterbury, N. V., & Egge, J. A. (2021) · Primary care diabetes · doi:10.1016/j.pcd.2021.01.014
McGrath, N. G., & Pillay, S. (2021) · Journal of Endocrinology Metabolism and Diabetes of South Africa · doi:10.1080/16089677.2021.1928982
Long-Term Glycemic Control for Stroke Survivors
Kang, D.-W. (2021) · Stroke revisited · doi:10.1007/978-981-16-5123-6_20
Evaluation of hyperalgesic effect of sitagliptin in albino mice
Mohan, L., Kumar, M., Kumar, M., Hameed, S., & Shekhar, A. (2021) · IP International Journal of Comprehensive and Advanced Pharmacology · doi:10.18231/j.ijcaap.2021.025
Mlotshwa, C. R. N., Burger, J. R., Vorster, M., Rakumakoe, D. M., & Cockeran, M. (2021) · Current Drug Safety · doi:10.2174/1574886316666211108103301
Neuromuscular Manifestations of Acquired Metabolic, Endocrine, and Nutritional Disorders
Bassam, B. A., & Bertorini, T. E. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-71317-7.00021-4
Hämoglobin A 1c: Die heutige Rolle für die therapeutische Entscheidung
Müller‐Wieland, D., & Marx, N. (2019) · Deutsches Ärzteblatt · doi:10.3238/persdia.2019.10.25.02
Schipf, S., Markus, M. R. P., & Dörr, M. (2019) · Springer Reference Pflege, Therapie, Gesundheit · doi:10.1007/978-3-662-55793-8_54-2 · Cited by 1
Freichel, M., & Mengel, K. (2020) · Springer eBooks · doi:10.1007/978-3-662-62168-4_12
Schipf, S., Markus, M. R. P., & Dörr, M. (2019) · Springer Reference Pflege, Therapie, Gesundheit · doi:10.1007/978-3-662-55793-8_54-1
Prevention of eating disorders in specialty care
del Portillo, R. C., Matía‐Martín, P., Castro, M. J., Olmos, M. Á. M., & Candela, C. G. (2022) · Nutrición Hospitalaria · doi:10.20960/nh.04188 · Cited by 1
Aguiar, E. D. N. S., Soares, J. S. S., & Pinto, M. D. N. (2023) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.8015305
Perioperatives Management bei alten Menschen mit Diabetes mellitus
Lee-Barkey, Y., & Stratmann, B. (2023) · Die Diabetologie · doi:10.1007/s11428-023-01093-6
21. Yüzyıl’da Sağlık Bilimleri: Yöntem, Kuram ve Vaka
Yıldız, E. K., & Tur, K. (2023) · Özgür Yayınları eBooks · doi:10.58830/ozgur.pub282
Assessment of cardiovascular effects of non-insulin blood-glucose-lowering agents
Comoglio, N. H. (2019) · theses.fr (ABES) · doi:10.70675/5005dc38zdb1cz426cz8401z845e901eb81b
Kumar, S., & Agarwal, V. K. (2023) · Journal of Medical Society · doi:10.4103/jms.jms_30_22
Benefícios cardiovasculares relacionados ao uso de fármacos inibidores da proteína SGLT-2
Ferreira, M. L., Coutinho, V. E. A., da Silva, M. F. A., Carolino, R. D. A., & Dantas, F. S. E. (2024) · Research Society and Development · doi:10.33448/rsd-v13i3.45349
Suzuki, R., Kazumori, K., Usui, T., & Shinohara, M. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14214
Pilla, S. J., Wang, I. J., Tang, O., Schoenborn, N. L., Boyd, C. M., Bancks, M. P., Mathioudakis, N. N., & Maruthur, N. M. (2024) · Clinical Diabetes · doi:10.2337/cd24-0043 · Cited by 1
Rouland, A. (2024) · theses.fr (ABES) · doi:10.70675/6af70b1eze632z469ez88c8zdb045a5e78c6
Liu, G., Yao, Y., Sun, J., Feng, H., Hu, B., Hu, W., Gu, H., Bu, R., & Jiang, Y. (2025) · BMJ Public Health · doi:10.1136/bmjph-2024-001245
Novel therapies – IMID Co-morbidities
Lam, T. T., So, H., & Tam, L. (2025) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2025.102089
Csatordai, M. (2025) · SZTE Repository of Dissertations (University of Szeged) · doi:10.14232/phd.12581
Sawalha, K., Alamat, L., Rana, A., Bruich, L., & Candales, A. L. (2025) · Cureus · doi:10.7759/cureus.97446
Alfayez, O. M., Almohammed, O. A., Alkhezi, O. S., Almutairi, A. R., & Al Yami, M. S. (2020) · Figshare · doi:10.6084/m9.figshare.12545036
Alfayez, O. M., Almohammed, O. A., Alkhezi, O. S., Almutairi, A. R., & Yami, M. S. A. (2020) · Figshare · doi:10.6084/m9.figshare.12544994
Alfayez, O. M., Almohammed, O. A., Alkhezi, O. S., Almutairi, A. R., & Yami, M. S. A. (2020) · Figshare · doi:10.6084/m9.figshare.12545009
Alfayez, O. M., Almohammed, O. A., Alkhezi, O. S., Almutairi, A. R., & Yami, M. S. A. (2020) · Figshare · doi:10.6084/m9.figshare.12545018
Gu, S., Shi, L., Shao, H., Wang, X., Hu, X., Gu, Y., & Dong, H. (2020) · Figshare · doi:10.6084/m9.figshare.13323724
Lin, S.-F., Chang, S., Kuo, C.-F., Lin, W.-T., Chiou, M.-J., & Huang, Y.-T. (2020) · Figshare · doi:10.6084/m9.figshare.12922819
Alfayez, O. M., Almohammed, O. A., Alkhezi, O. S., Almutairi, A. R., & Al Yami, M. S. (2020) · Figshare · doi:10.6084/m9.figshare.12545000
Eby, E. L., Edwards, A. M., Meadows, E. S., Lipkovich, I. A., Benneyworth, B. D., & Snow, K. J. (2021) · Figshare · doi:10.6084/m9.figshare.14936221
Alfayez, O. M., Almohammed, O. A., Alkhezi, O. S., Almutairi, A. R., & Al Yami, M. S. (2020) · Figshare · doi:10.6084/m9.figshare.12544985
Alfayez, O. M., Almohammed, O. A., Alkhezi, O. S., Almutairi, A. R., & Al Yami, M. S. (2020) · Figshare · doi:10.6084/m9.figshare.12545027
Cha, A. S. (2020) · ResearchWorks at the University of Washington (University of Washington)
Wang, W., Reynier, P., Webster‐Clark, M., Yu, O. H. Y., Brunetti, V. C., & Filion, K. B. (2026) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.70313
Murane, N., Sprūdža, K. L., Ivanova, J., & Zaļizko, P. (2025) · Consilium Medicum · doi:10.26442/20751753.2025.12.203494
Review Article on Diabetic-Bearded Women Syndrome
Shalini, S., Patel Bansari, B., & Jacob, D. M. (2026) · International Journal of Nursing Education and Research · doi:10.52711/2454-2660.2026.00016
Gutierrez, S. F. (2020) · theses.fr (ABES) · doi:10.70675/67bbdcd2z3827z4bcbz87efzb280ed04bc58
Semiz, G. G., Ünal, M. Ç., Selimoğlu, İ., Kalender, S., Erbay, E., Arayıcı, M. E., Çömlekçi, A., Yener, S., & Demir, T. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15093529
“In patients with T2DM, treatment intensification with basal insulin is a recommended strategy, though it may be influenced by various clinical considerations [3,4].”
Irby, J., Lehnardt, E., Rasizer, L. N., Payton, M. E., & Ryznar, R. J. (2026) · JMIR Formative Research · doi:10.2196/preprints.103864
Baayou, M. (2026) · مجلة البحوث الأكاديمية · doi:10.65540/jar.v30i.1595
Distúrbios do metabolismo dos hidratos de carbono na síndrome dos ovários policísticos
Barcellos, C. R. G. (2019) · Femina · doi:10.61622/0100-7254478201907
Parab, K. V. (2024) · Illinois Digital Environment for Access to Learning and Scholarship (University of Illinois at Urbana-Champaign)
Comparative Analysis of SGLT-2 Inhibitors and GLP-1 Agonists in the Treatment of Type 2 Diabetes
Rashid, I., Ain, Q. U., Safeer, F., Zubir, T., Khushhal, S., Faisal, M., Majeed, A., Ayesha, Ishaque, K., kazmi, S. A., et al. (2026) · Social science review archives.
Oral Health–Related Adverse Events of GLP-1 Receptor Agonists
Massarotto, F. C., Mahmoud, A. H., Watson, G. E., & Arany, S. (2026) · JDR Clinical & Translational Research · doi:10.1177/23800844261491724
Metadata
- Authors
- American Diabetes Association
- Corresponding author
- American Diabetes Association
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2018-12-07
- Volume
- 42
- Issue
- Supplement_1
- Pages
- S90-S102
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4212810717
- Cited by
- 739
- References
- 81
- Citations by year
- 2026: 12 · 2025: 28 · 2024: 30 · 2023: 47 · 2022: 69 · 2021: 126 · 2020: 246 · 2019: 181
- FWCI
- 21.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- glycemic control, pharmacotherapy, antidiabetic drugs, treatment goals, quality of care, clinical guidelines
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Societies, Medical, United States, Practice Guidelines as Topic, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.